Engineering T cells with a chimeric antigen receptor (CAR) that reprograms their antigen selectivity and signalling has recently emerged as one of the most promising therapeutic approaches for treating cancers. The initial emergence and the evolution of this treatment has significantly contributed to its success. However, it is not known if the advancement of this technology is accompanied with any socio- economic or ethical concerns. This paper will first dive into the scientific evolution of CAR T-cell therapy as mode of cancer treatment. In addition, this paper will also describe the basic structure of the CAR and discuss how each of its domains affect the efficacy and safety of CAR-T therapies. It will also highlight the changing landscape of ethical concerns raised by CAR T-cell therapy. Overall, this paper analyzes how the advancement in CAR T-Cell therapy has or will impact public opinion and health.